Rationale and Design of Prospective, Multicenter, Double-Arm Clinical Trial to Investigate the Efficacy of Tofogliflozin on Left Ventricular Diastolic Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus (TOP-HFPEF Trial).
Shin ItoYuri NakajimaHiroki FukudaChisato IzumiGaku NakazawaHajime YamashitaHideo MatsuhisaMoriaki InokoShigeru ToyodaShin TakiuchiToru KataokaYasuhiro IzumiyaYukio AbeTakashi SozuYasushi SakataMasanori EmotoTeruo InoueMasafumi KitakazePublished in: Cardiovascular drugs and therapy (2024)
The TOP-HFPEF trial will clarify the efficacy of an SGLT2 inhibitor, tofogliflozin, on LV diastolic function in patients with HFpEF and type 2 diabetes mellitus.
Keyphrases
- left ventricular
- clinical trial
- phase iii
- phase ii
- study protocol
- hypertrophic cardiomyopathy
- glycemic control
- blood pressure
- double blind
- open label
- cardiac resynchronization therapy
- acute myocardial infarction
- heart failure
- mitral valve
- aortic stenosis
- oxidative stress
- left atrial
- ejection fraction
- randomized controlled trial
- cardiovascular risk factors
- type diabetes
- insulin resistance
- adipose tissue
- skeletal muscle